Cariprazine as an adjunct therapy for treatment of negative symptoms in patients with Schizophrenia – A randomized double blind placebo controlled trial

Central Institute of Psychiatry0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1) Schizophrenia diagnosed patients according to International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, ICD-10 Diagnostic criteria.
•2) 20–55 years of age.
•3) Disease course >2years.
•4) PANSS negative symptoms score =4 in at least four items or =15 combined.
•5) PANSS positive symptoms score =4 in at least three items or =10 combined.
•6) CDSS score <6 and SAS score <3
•7) Patients receiving treatment for schizophrenia with preferably second generation anti¬-psychotic
•8)Those who give informed consent for
•participating in the study.

•1.Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.
•2.Significant medical or neurological illness including severe cardiovascular, hepatic, renal, [serum creatinine > 1.5 mg/dl], anaemia [Haemoglobin < 11 mg/dl], or myopathy or untreated thyroid disease.
•3.History of substantial brain damage or any neurological disorders.
•4.Pregnancy
•5.Patients receiving treatment with any first-generation anti-psychotic / depot or long-acting anti-psychotic / anti-depressant.

发起方